TY - STD TI - Cancer Research UK. Thyroid cancer incidence statistics www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/thyroid-cancer/incidence. Acessed 5 May 2017. UR - http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/thyroid-cancer/incidence ID - ref1 ER - TY - STD TI - National Cancer Institute S, Epidemiology, and End Results Program,. Cancer Stat Facts: Thyroid Cancer https://seer.cancer.gov/statfacts/html/thyro.html. Acessed 4 June 2018. UR - https://seer.cancer.gov/statfacts/html/thyro.html ID - ref2 ER - TY - JOUR AU - Bomeli, S. R. AU - LeBeau, S. O. AU - Ferris, R. L. PY - 2010 DA - 2010// TI - Evaluation of a thyroid nodule JO - Otolaryngol Clin N Am VL - 43 UR - https://doi.org/10.1016/j.otc.2010.01.002 DO - 10.1016/j.otc.2010.01.002 ID - Bomeli2010 ER - TY - JOUR AU - Jonklaas, J. AU - Sarlis, N. J. AU - Litofsky, D. AU - Ain, K. B. AU - Bigos, S. T. AU - Brierley, J. D. AU - Cooper, D. S. AU - Haugen, B. R. AU - Ladenson, P. W. AU - Magner, J. PY - 2006 DA - 2006// TI - Outcomes of patients with differentiated thyroid carcinoma following initial therapy JO - Thyroid VL - 16 UR - https://doi.org/10.1089/thy.2006.16.1229 DO - 10.1089/thy.2006.16.1229 ID - Jonklaas2006 ER - TY - JOUR AU - Vecchia, C. AU - Malvezzi, M. AU - Bosetti, C. AU - Garavello, W. AU - Bertuccio, P. AU - Levi, F. AU - Negri, E. PY - 2015 DA - 2015// TI - Thyroid cancer mortality and incidence: a global overview JO - Int J Cancer VL - 136 UR - https://doi.org/10.1002/ijc.29251 DO - 10.1002/ijc.29251 ID - Vecchia2015 ER - TY - JOUR AU - Davies, L. AU - Welch, H. G. PY - 2006 DA - 2006// TI - Increasing incidence of thyroid cancer in the United States, 1973-2002 JO - JAMA VL - 295 UR - https://doi.org/10.1001/jama.295.18.2164 DO - 10.1001/jama.295.18.2164 ID - Davies2006 ER - TY - JOUR AU - Haugen, B. R. AU - Alexander, E. K. AU - Bible, K. C. AU - Doherty, G. M. AU - Mandel, S. J. AU - Nikiforov, Y. E. AU - Pacini, F. AU - Randolph, G. W. AU - Sawka, A. M. AU - Schlumberger, M. PY - 2016 DA - 2016// TI - 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid Cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid Cancer JO - Thyroid VL - 26 UR - https://doi.org/10.1089/thy.2015.0020 DO - 10.1089/thy.2015.0020 ID - Haugen2016 ER - TY - JOUR AU - Pacini, F. AU - Castagna, M. G. AU - Brilli, L. AU - Pentheroudakis, G. PY - 2012 DA - 2012// TI - Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up JO - Ann Oncol VL - 23 UR - https://doi.org/10.1093/annonc/mds230 DO - 10.1093/annonc/mds230 ID - Pacini2012 ER - TY - JOUR AU - Perros, P. AU - Boelaert, K. AU - Colley, S. AU - Evans, C. AU - Evans, R. M. AU - Gerrard Ba, G. AU - Gilbert, J. AU - Harrison, B. AU - Johnson, S. J. AU - Giles, T. E. PY - 2014 DA - 2014// TI - Guidelines for the Management of Thyroid Cancer, third edition JO - Clin Endocrinol VL - 81 UR - https://doi.org/10.1111/cen.12515 DO - 10.1111/cen.12515 ID - Perros2014 ER - TY - BOOK PY - 2017 DA - 2017// TI - NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma. Version 1 ID - ref10 ER - TY - JOUR AU - Brose, M. S. PY - 2012 DA - 2012// TI - In search of a real “targeted” therapy for thyroid cancer JO - Clin Cancer Res VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-12-0153 DO - 10.1158/1078-0432.CCR-12-0153 ID - Brose2012 ER - TY - JOUR AU - Busaidy, N. a. i. f. a. L. a. m. k. i. AU - Cabanillas, M. a. r. i. a. E. PY - 2012 DA - 2012// TI - Differentiated Thyroid Cancer: Management of Patients with Radioiodine Nonresponsive Disease JO - Journal of Thyroid Research VL - 2012 UR - https://doi.org/10.1155/2012/618985 DO - 10.1155/2012/618985 ID - Busaidy2012 ER - TY - JOUR AU - Schlumberger, M. AU - Challeton, C. AU - Vathaire, F. AU - Travagli, J. P. AU - Gardet, P. AU - Lumbroso, J. D. AU - Francese, C. AU - Fontaine, F. AU - Ricard, M. AU - Parmentier, C. PY - 1996 DA - 1996// TI - Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma JO - J Nucl Med VL - 37 ID - Schlumberger1996 ER - TY - JOUR AU - Durante, C. AU - Haddy, N. AU - Baudin, E. AU - Leboulleux, S. AU - Hartl, D. AU - Travagli, J. P. AU - Caillou, B. AU - Ricard, M. AU - Lumbroso, J. D. AU - Vathaire, F. PY - 2006 DA - 2006// TI - Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy JO - J Clin Endocrinol Metab VL - 91 UR - https://doi.org/10.1210/jc.2005-2838 DO - 10.1210/jc.2005-2838 ID - Durante2006 ER - TY - JOUR AU - Newbold, K. L. AU - Flux, G. AU - Wadsley, J. PY - 2017 DA - 2017// TI - Radioiodine for high risk and radioiodine refractory thyroid Cancer: current concepts in management JO - Clin Oncol (R Coll Radiol) VL - 29 UR - https://doi.org/10.1016/j.clon.2016.12.008 DO - 10.1016/j.clon.2016.12.008 ID - Newbold2017 ER - TY - STD TI - Food and Drug Administration. Lenvatinib (Lenvima). Page Last Updated: 02/13/2015 https://wayback.archive-it.org/7993/20170111231641/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm434347.htm. Acessed 16 May 2017. UR - https://wayback.archive-it.org/7993/20170111231641/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm434347.htm ID - ref16 ER - TY - STD TI - European Medicines Agency. Product information: 23/03/2017 Lenvima -EMEA/H/C/003727 -WS/1123. Annex I - Summary of product characteristics. First published: 25/06/2015. Last updated: 24/04/2017 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003727/WC500188674.pdf. Acessed 10 May 2017. UR - http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003727/WC500188674.pdf ID - ref17 ER - TY - STD TI - Food and Drug Administration. Sorafenib (Nexavar). Page Last Updated: 10/14/2015. https://wayback.archive-it.org/7993/20170111231704/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm376547.htm. Acessed 16 May 2017. UR - https://wayback.archive-it.org/7993/20170111231704/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm376547.htm ID - ref18 ER - TY - STD TI - European Medicines Agency. Product information: 02/09/2016 Nexavar -EMEA/H/C/000690 -N/38. Annex I - Summary of product characteristics. First published: 21/12/2009. Last updated: 30/09/2016 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000690/WC500027704.pdf. Acessed 10 May 2017. UR - http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000690/WC500027704.pdf ID - ref19 ER - TY - STD TI - Scottish Medicines Consortium sorafenib 200mg film-coated tablets (Nexavar®) SMC No. (1055/15). 05 June 2015 https://www.scottishmedicines.org.uk/files/advice/sorafenib_Nexavar_FINAL_June_2015_for_website.pdf. Acessed 10 May 2018. UR - https://www.scottishmedicines.org.uk/files/advice/sorafenib_Nexavar_FINAL_June_2015_for_website.pdf ID - ref20 ER - TY - STD TI - Scottish Medicines Consortium lenvatinib 4mg and 10mg hard capsules (Lenvima®) SMC No. (1179/16). 09 September 2016 https://www.scottishmedicines.org.uk/files/advice/lenvatinib_Lenvima_FINAL_Sept_2016_amended_30.09.16_for_website.pdf. Acessed 17 November 2016. UR - https://www.scottishmedicines.org.uk/files/advice/lenvatinib_Lenvima_FINAL_Sept_2016_amended_30.09.16_for_website.pdf ID - ref21 ER - TY - STD TI - Centre for Reviews and Dissemination. Systematic Reviews: CRD’s guidance for undertaking reviews in healthcare. http://www.york.ac.uk/crd/SysRev/!SSL!/WebHelp/SysRev3.htm#5_5_QUALITY_ASSESSMENT.htm. Acessed 24 Jan 2017. UR - http://www.york.ac.uk/crd/SysRev/!SSL!/WebHelp/SysRev3.htm#5_5_QUALITY_ASSESSMENT.htm ID - ref22 ER - TY - JOUR AU - Moher, D. AU - Liberati, A. AU - Tetzlaff, J. AU - Altman, D. G. PY - 2009 DA - 2009// TI - Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement JO - BMJ VL - 339 UR - https://doi.org/10.1136/bmj.b2535 DO - 10.1136/bmj.b2535 ID - Moher2009 ER - TY - STD TI - Eisai Ltd. Multiple technology appraisal [ID1059]. Lenvatinib for treating differentiated thyroid cancer after radioactive iodine. Eisai submission. April 2017 https://www.nice.org.uk/guidance/gid-ta10101/documents/committee-papers. Acessed 30 July 2018. UR - https://www.nice.org.uk/guidance/gid-ta10101/documents/committee-papers ID - ref24 ER - TY - STD TI - Bayer HealthCare. Multiple technology appraisal. Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine. Company submission to NICE. March 2017 https://www.nice.org.uk/guidance/gid-ta10101/documents/committee-papers. Acessed 30 July 2018. UR - https://www.nice.org.uk/guidance/gid-ta10101/documents/committee-papers ID - ref25 ER - TY - JOUR AU - Schlumberger, M. AU - Tahara, M. AU - Wirth, L. J. AU - Robinson, B. AU - Brose, M. S. AU - Elisei, R. AU - Habra, M. A. AU - Newbold, K. AU - Shah, M. H. AU - Hoff, A. O. PY - 2015 DA - 2015// TI - Lenvatinib versus placebo in radioiodine-refractory thyroid cancer JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1406470 DO - 10.1056/NEJMoa1406470 ID - Schlumberger2015 ER - TY - JOUR AU - Brose, M. S. AU - Nutting, C. M. AU - Jarzab, B. AU - Elisei, R. AU - Siena, S. AU - Bastholt, L. AU - Fouchardiere, C. AU - Pacini, F. AU - Paschke, R. AU - Shong, Y. K. PY - 2014 DA - 2014// TI - Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial JO - Lancet VL - 384 UR - https://doi.org/10.1016/S0140-6736(14)60421-9 DO - 10.1016/S0140-6736(14)60421-9 ID - Brose2014 ER - TY - JOUR AU - Ahmed, M. AU - Barbachano, Y. AU - Riddell, A. AU - Hickey, J. AU - Newbold, K. L. AU - Viros, A. AU - Harrington, K. J. AU - Marais, R. AU - Nutting, C. M. PY - 2011 DA - 2011// TI - Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population JO - Eur J Endocrinol VL - 165 UR - https://doi.org/10.1530/EJE-11-0129 DO - 10.1530/EJE-11-0129 ID - Ahmed2011 ER - TY - JOUR AU - Cabanillas, M. E. AU - Schlumberger, M. AU - Jarzab, B. AU - Martins, R. G. AU - Pacini, F. AU - Robinson, B. AU - McCaffrey, J. C. AU - Shah, M. H. AU - Bodenner, D. L. AU - Topliss, D. PY - 2015 DA - 2015// TI - A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment JO - Cancer VL - 121 UR - https://doi.org/10.1002/cncr.29395 DO - 10.1002/cncr.29395 ID - Cabanillas2015 ER - TY - JOUR AU - Chen, L. PY - 2011 DA - 2011// TI - Sorafenib at a low dose against radioiodinerefractory metastatic papillary thyroid carcinoma in lung JO - Thyroid VL - 21 ID - Chen2011 ER - TY - JOUR AU - Duntas, L. H. AU - Vlassopoulou, V. AU - Boutsiadis, A. AU - Mantzou, E. AU - Anapliotou, M. AU - Tsatsoulis, A. PY - 2011 DA - 2011// TI - Sorafenib in the treatment of radioiodine refractory thyroid cancer. A multicenter phase II study JO - Eur Thyroid J VL - 0 ID - Duntas2011 ER - TY - JOUR AU - Gupta-Abramson, V. AU - Troxel, A. B. AU - Nellore, A. AU - Puttaswamy, K. AU - Redlinger, M. AU - Ransone, K. AU - Mandel, S. J. AU - Flaherty, K. T. AU - Loevner, L. A. AU - O'Dwyer, P. J. PY - 2008 DA - 2008// TI - Phase II trial of sorafenib in advanced thyroid cancer JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2008.16.3279 DO - 10.1200/JCO.2008.16.3279 ID - Gupta-Abramson2008 ER - TY - JOUR AU - Kloos, R. T. AU - Ringel, M. D. AU - Knopp, M. V. AU - Hall, N. C. AU - King, M. AU - Stevens, R. AU - Liang, J. AU - Wakely, P. E. AU - Vasko, V. V. AU - Saji, M. PY - 2009 DA - 2009// TI - Phase II trial of sorafenib in metastatic thyroid cancer JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.18.2717 DO - 10.1200/JCO.2008.18.2717 ID - Kloos2009 ER - TY - JOUR AU - Marotta, V. AU - Sciammarella, C. AU - Capasso, M. AU - Testori, A. AU - Pivonello, C. AU - Chiofalo, M. G. AU - Pivonello, R. AU - Pezzullo, L. AU - Botti, G. AU - Colao, A. PY - 2016 DA - 2016// TI - Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib JO - Endocrine VL - 16 ID - Marotta2016 ER - TY - JOUR AU - Schneider, T. C. AU - Abdulrahman, R. M. AU - Corssmit, E. P. AU - Morreau, H. AU - Smit, J. W. AU - Kapiteijn, E. PY - 2012 DA - 2012// TI - Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial JO - Eur J Endocrinol VL - 167 UR - https://doi.org/10.1530/EJE-12-0405 DO - 10.1530/EJE-12-0405 ID - Schneider2012 ER - TY - JOUR AU - Takahashi, S. h. u. n. j. i. AU - Kiyota, N. a. o. m. i. AU - Yamazaki, T. o. m. o. k. o. AU - Chayahara, N. a. o. k. o. AU - Nakano, K. e. n. j. i. AU - INAGAKI, L. I. N. A. AU - Toda, K. a. z. u. h. i. s. a. AU - Enokida, T. o. m. o. h. i. r. o. AU - Minami, H. i. r. o. n. o. b. u. AU - Imamura, Y. o. s. h. i. n. o. r. i. AU - Sasaki, T. a. t. s. u. y. a. AU - Suzuki, T. a. k. u. y. a. AU - Fujino, K. a. t. s. u. k. i. AU - Dutcus, C. o. r. i. n. a. AU - Tahara, M. a. k. o. t. o. PY - 2016 DA - 2016// TI - Phase II study of lenvatinib in patients with differentiated, medullary, and anaplastic thyroid cancer: Final analysis results JO - Journal of Clinical Oncology VL - 34 UR - https://doi.org/10.1200/JCO.2016.34.15_suppl.6088 DO - 10.1200/JCO.2016.34.15_suppl.6088 ID - Takahashi2016 ER - TY - JOUR AU - Anderson, R. T. AU - Linnehan, J. E. AU - Tongbram, V. AU - Keating, K. AU - Wirth, L. J. PY - 2013 DA - 2013// TI - Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review JO - Thyroid VL - 23 UR - https://doi.org/10.1089/thy.2012.0520 DO - 10.1089/thy.2012.0520 ID - Anderson2013 ER - TY - STD TI - Canadian Agency for Drugs and Technologies in Health. pan-Canadian Oncology Drug Review Final Clinical Guidance Report Sorafenib (Nexavar) for Differentiated Thyroid Cancer https://www.cadth.ca/sites/default/files/pcodr/pcodr_sorafenib_nexavar_dtc_fn_cgr.pdf. Acessed 16 May 2017. UR - https://www.cadth.ca/sites/default/files/pcodr/pcodr_sorafenib_nexavar_dtc_fn_cgr.pdf ID - ref38 ER - TY - STD TI - Canadian Agency for Drugs and Technologies in Health. pan-Canadian Oncology Drug Review Final Clinical Guidance Report: Lenvatinib (Lenvima) for Differentiated Thyroid Cancer https://www.cadth.ca/sites/default/files/pcodr/pcodr_lenvatinib_lenvima_dtc_fn_cgr.pdf. Acessed 16 May 2017. UR - https://www.cadth.ca/sites/default/files/pcodr/pcodr_lenvatinib_lenvima_dtc_fn_cgr.pdf ID - ref39 ER - TY - JOUR AU - Gruber, J. J. AU - Colevas, A. D. PY - 2015 DA - 2015// TI - Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients JO - Oncologist VL - 20 UR - https://doi.org/10.1634/theoncologist.2014-0313 DO - 10.1634/theoncologist.2014-0313 ID - Gruber2015 ER - TY - JOUR AU - Jean, G. W. AU - Mani, R. M. AU - Jaffry, A. AU - Khan, S. A. PY - 2016 DA - 2016// TI - Toxic effects of Sorafenib in patients with differentiated thyroid carcinoma compared with other cancers JO - JAMA Oncol VL - 2 UR - https://doi.org/10.1001/jamaoncol.2015.5927 DO - 10.1001/jamaoncol.2015.5927 ID - Jean2016 ER - TY - JOUR AU - Kawalec, P. AU - Malinowska-Lipien, I. AU - Brzostek, T. AU - Kozka, M. PY - 2016 DA - 2016// TI - Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib JO - Expert Rev Anticancer Ther VL - 16 UR - https://doi.org/10.1080/14737140.2016.1247697 DO - 10.1080/14737140.2016.1247697 ID - Kawalec2016 ER - TY - JOUR AU - McFarland, D. C. AU - Misiukiewicz, K. J. PY - 2014 DA - 2014// TI - Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer JO - Onco Targets Ther VL - 7 UR - https://doi.org/10.2147/OTT.S49430 DO - 10.2147/OTT.S49430 ID - McFarland2014 ER - TY - JOUR AU - Shen, C. T. AU - Qiu, Z. L. AU - Luo, Q. Y. PY - 2014 DA - 2014// TI - Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis JO - Endocr Relat Cancer VL - 21 UR - https://doi.org/10.1530/ERC-13-0438 DO - 10.1530/ERC-13-0438 ID - Shen2014 ER - TY - JOUR AU - Thomas, L. AU - Lai, S. Y. AU - Dong, W. AU - Feng, L. AU - Dadu, R. AU - Regone, R. M. AU - Cabanillas, M. E. PY - 2014 DA - 2014// TI - Sorafenib in metastatic thyroid cancer: a systematic review JO - Oncologist VL - 19 UR - https://doi.org/10.1634/theoncologist.2013-0362 DO - 10.1634/theoncologist.2013-0362 ID - Thomas2014 ER - TY - JOUR AU - Tremblay, G. AU - Holbrook, T. AU - Milligan, G. AU - Pelletier, C. AU - Rietscheli, P. PY - 2016 DA - 2016// TI - Matching-adjusted indirect treatment comparison in patients with radioiodine-refractory differentiated thyroid cancer JO - Comp Eff Res VL - 6 ID - Tremblay2016 ER - TY - JOUR AU - Ye, X. AU - Zhu, Y. AU - Cai, J. PY - 2015 DA - 2015// TI - Relationship between toxicities and clinical benefits of newly approved tyrosine kinase inhibitors in thyroid cancer: a meta-analysis of literature JO - J Cancer Res Ther VL - 11 UR - https://doi.org/10.4103/0973-1482.168182 DO - 10.4103/0973-1482.168182 ID - Ye2015 ER - TY - JOUR AU - Haddad, R. AU - Schlumberger, M. AU - Wirth, L. AU - Sherman, E. AU - Shah, M. H. AU - Robinson, B. AU - Ductus, C. AU - Teng, A. AU - Gianoukakis, A. AU - Sherman, S. I. PY - 2015 DA - 2015// TI - Incidence and timing of common adverse events in lenvatinib-treated patients with radioiodine-refractory thyroid cancer from the select trial JO - Thyroid VL - 25 ID - Haddad2015 ER - TY - JOUR AU - Newbold, K. AU - Elisei, R. AU - Taylor, M. H. AU - Krzyzanowska, M. AU - Shah, M. H. AU - Hoff, A. O. AU - Robinson, B. AU - Dutcus, C. AU - Song, J. AU - Hughes, B. PY - 2015 DA - 2015// TI - Efficacy and safety of lenvatinib for the treatment of patients with 131i-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy JO - Asia Pac J Clin Oncol VL - 11 ID - Newbold2015 ER - TY - JOUR AU - Newbold, K. AU - Elisei, R. AU - Taylor, M. H. AU - Krzyzanowska, M. K. AU - Shah, M. H. AU - Hoff, A. O. AU - Robinson, B. AU - Dutcus, C. AU - Song, J. AU - Habra, M. A. PY - 2015 DA - 2015// TI - Efficacy and safety of lenvatinib for the treatment of patients with 131 I-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/jco.2015.33.15_suppl.6013 DO - 10.1200/jco.2015.33.15_suppl.6013 ID - Newbold2015 ER - TY - STD TI - European Medicines Agency. Assessment report. Lenvima. International non-proprietary name: lenvatinib. Procedure No. EMEA/H/C/003727/0000. Committee for Medicinal Products for Human Use (CHMP). EMA/250082/2015. 30. London, 26 March 2015 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003727/WC500188676.pdf. Acessed 10 May 2017. UR - http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003727/WC500188676.pdf ID - ref51 ER - TY - JOUR AU - Worden, F. AU - Fassnacht, M. AU - Shi, Y. AU - Hadjieva, T. AU - Bonichon, F. AU - Gao, M. AU - Fugazzola, L. AU - Ando, Y. AU - Hasegawa, Y. AU - Park do, J. PY - 2015 DA - 2015// TI - Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer JO - Endocr Relat Cancer VL - 22 UR - https://doi.org/10.1530/ERC-15-0252 DO - 10.1530/ERC-15-0252 ID - Worden2015 ER - TY - JOUR AU - Paschke, R. AU - Schlumberger, M. AU - Nutting, C. AU - Jarzab, B. AU - Elisei, R. AU - Siena, S. AU - Bastholt, L. AU - Fouchardiere, C. AU - Pacini, F. AU - Shong, Y. K. PY - 2015 DA - 2015// TI - Exploratory analysis of outcomes for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) receiving open-label sorafenib post-progression on the phase III DECISION trial JO - Oncol Res Treat VL - 38 ID - Paschke2015 ER - TY - JOUR AU - Schlumberger, M. AU - Nutting, C. AU - Jarzab, B. AU - Elisei, R. AU - Siena, S. AU - Bastholt, L. AU - Fouchardiere, C. AU - Pacini, F. AU - Paschke, R. AU - Shong, Y. K. PY - 2014 DA - 2014// TI - Exploratory analysis of outcomes for patients with locally advanced or metastatic radioactive iodinerefractory differentiated thyroid cancer (RAI-rDTC) receiving open-label sorafenib post-progression on the phase III decision trial JO - Eur Thyroid J VL - 3 UR - https://doi.org/10.1159/000358590 DO - 10.1159/000358590 ID - Schlumberger2014 ER - TY - JOUR AU - Schlumberger, M. AU - Jarzab, B. AU - Elisei, R. AU - Siena, S. AU - Bastholt, L. AU - Fouchardiere, C. AU - Pacini, F. AU - Paschke, R. AU - Worden, F. AU - Bockisch, A. PY - 2013 DA - 2013// TI - Phase III randomized, double-blinded, placebocontrolled trial of sorafenib in locally advanced or metastatic patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC)-exploratory analyses of patient-reported outcomes JO - Thyroid VL - 23 ID - Schlumberger2013 ER - TY - STD TI - European Medicines Agency. CHMP extension of indication variation assessment report: Nexavar. Procedure no.: EMEA/H/C/000690/II/0035. Committee for Medicinal Products for Human Use (CHMP). EMA/CHMP/220738/2014. London, 25 April 2014 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000690/WC500168976.pdf. Acessed 10 May 2017. UR - http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000690/WC500168976.pdf ID - ref56 ER - TY - STD TI - Terry RD, Keefe SM, Grande CM, Zifchak L, Brose MS. Timing and severity of skin-related adverse events in a phase II trial of sorafenib (BAY43–9006) in patients with advanced thyroid cancer. J Clin Oncol. 2013;31(15 Suppl). https://doi.org/10.1200/jco.2013.1231.1215_suppl.e17009. ID - ref57 ER - TY - JOUR AU - Brose, M. S. AU - Troxel, A. B. AU - Harlacker, K. AU - Redlinger, M. AU - Chalian, A. A. AU - Loevner, L. A. AU - Mandel, S. J. AU - O’Dwyer, P. J. AU - Keefe, S. M. PY - 2009 DA - 2009// TI - Completion of a phase II study of sorafenib for advanced thyroid cancer JO - Eur J Cancer VL - 7 ID - Brose2009 ER - TY - JOUR AU - Keefe, S. M. AU - Troxel, A. B. AU - Rhee, S. AU - Puttaswamy, K. AU - O'Dwyer, P. J. AU - Loevner, L. A. AU - Mandel, S. J. AU - Brose, M. S. PY - 2011 DA - 2011// TI - Phase II trial of sorafenib in patients with advanced thyroid cancer JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/jco.2011.29.15_suppl.5562 DO - 10.1200/jco.2011.29.15_suppl.5562 ID - Keefe2011 ER - TY - JOUR AU - Robins, J. M. AU - Tsiatis, A. A. PY - 1991 DA - 1991// TI - Correcting for non-compliance in randomized trials using rank preserving structural failure time models JO - Commun Stat Theory Methods VL - 20 UR - https://doi.org/10.1080/03610929108830654 DO - 10.1080/03610929108830654 ID - Robins1991 ER - TY - JOUR AU - Cox, D. R. PY - 1972 DA - 1972// TI - Regression models and life-tables JO - J R Stat Soc Ser B VL - 34 ID - Cox1972 ER - TY - JOUR AU - Webster, K. AU - Cella, D. AU - Yost, K. PY - 2003 DA - 2003// TI - The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation JO - Health Qual Life Outcomes VL - 1 UR - https://doi.org/10.1186/1477-7525-1-79 DO - 10.1186/1477-7525-1-79 ID - Webster2003 ER - TY - JOUR PY - 1990 DA - 1990// TI - The EuroQol Group EuroQol--a new facility for the measurement of health-related quality of life JO - Health Policy VL - 16 UR - https://doi.org/10.1016/0168-8510(90)90421-9 DO - 10.1016/0168-8510(90)90421-9 ID - ref63 ER - TY - STD TI - National Institute for Health and Care Excellence (NICE). Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine [ID1059]. Expected publication date: 8 August 2018 https://www.nice.org.uk/guidance/gid-ta10101/documents/html-content-2. Acessed 16 May 2018. UR - https://www.nice.org.uk/guidance/gid-ta10101/documents/html-content-2 ID - ref64 ER -